Skip to main content
Fig. 4 | BMC Dermatology

Fig. 4

From: A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis

Fig. 4

Proportion of patients achieving (a) PASI 75, (b) PASI 50, and (c) PGA clear/almost-clear at each visit. ACT, acitretin; ETN, etanercept; PASI, Psoriasis Area Severity Index; PGA, Physician’s Global Assessment. *p < 0.05; **p < 0.0005

Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us